2 Communication Styles That Create Distance In Love, By A Psychologist
Some of the most painful moments in relationships stem from subtle communication habits that protect ... More instead of connect. Here are two that can slowly push partners apart.
Emotional distance in long-term relationships rarely begins with a major rupture. Instead, it often starts with subtle, recurring patterns such as missed cues, unmet bids for connection and conversations that leave one or both partners feeling unseen. These moments can easily compound into a quiet loneliness, even in the presence of physical closeness.
Statements such as the following often signal relationship decline.
These are not always problems of compatibility or conflict — they are symptoms of disconnection. At the root of disconnection are repeated micro-moments of misattunement in how we speak and listen to each other.
Certain communication styles, when habitual, signal a deeper emotional shift: from reaching toward one another to protecting oneself from vulnerability.
Here are the two communication styles that predict long-term disconnection in relationships.
Dismissive responding often hides behind a mask of calm rationality:
On the surface, these statements can sound composed or even well-meaning. But underneath lies a pattern of emotional invalidation. When one partner repeatedly minimizes, redirects or shuts down emotional expression, it sends a powerful message: 'Your feelings don't belong here.' Over time, the other person learns that to stay close, they have to shut off parts of themselves.
Research published in the Journal of the American Psychoanalytic Association found that emotionally distant individuals are not detached due to apathy, but because emotional closeness feels threatening. This defense often stems from early experiences as children, where their emotions were inadequately mirrored by a caregiver. Without consistent emotional attunement, the child develops a fragile identity, one that is built around the need to avoid vulnerability to preserve a sense of self.
In adult relationships, this manifests as a retreat into logic, control or detachment whenever emotions surface. Dismissiveness, then, becomes a self-protective strategy — less about ignoring the other person's feelings, and more about preserving a shaky internal equilibrium. Emotional expression feels overwhelming, and validation feels like a step too close to engulfment or loss of self.
As this pattern persists, the relationship begins to feel emotionally sterile. Conversations revolve around tasks. Vulnerability is edited out. One partner withdraws and the other goes silent because they never learned how to stay present with difficult feelings.
Repair, in this case, begins with presence over problem-solving. Instead of fixing, slow down and feel. Simple responses can open the door to connection:
Remember, validation doesn't necessarily mean agreement, it means making room for your partner's emotional reality without trying to alter it. For emotionally distant individuals, learning to tolerate this kind of closeness is not just about better communication, but about healing long-standing fears of intimacy and identity erosion.
Scorekeeping in relationships rarely stems from a genuine pursuit of fairness. Instead, it stems from emotional depletion. When one or both partners keep a running tally of who did more, gave more or tried harder, it's often an attempt to communicate unspoken pain such as, 'I feel invisible,' or 'I don't feel safe asking for what I need.'
Resentment begins to replace vulnerability. It might sound like:
But deep down, it's not about chores or calendars. Instead, it's about longing for recognition, balance and relief.
A 2013 study published in Contemporary Psychoanalysis highlights how couples often frame their struggles in moral language, invoking ideas of fairness, justice and responsibility.
While these frameworks may appear principled, they often mask the discomfort of vulnerability in intimate relationships. Drawing from psychoanalytic and attachment theory, the study suggests that this preoccupation with fairness can act as a defense against the anxiety of seeking emotional need fulfilment and healthy dependence.
In practice, this means scorekeeping becomes a relational shield or an emotionally distant way to ask for closeness. When couples focus on who owes whom, it prevents them from acknowledging the softer truth: 'I need more from you, and I don't know how to say it without feeling exposed.'
In real life, this turns scorekeeping into a substitute for closeness. Instead of saying, 'I'm hurting and I need more from you,' couples fall into a pattern of tit-for-tat. The relationship becomes transactional and all acts of love feel calculated, accompanied by hidden caveats.
To course coorect, you must look beneath the ledger and listen for the longing. Ask yourself:
Then, shift from tallying to tending. Instead of: 'I did the dishes three times this week,' try: 'I've been feeling burnt out. Could you take over the dishes tomorrow so I can recharge?'
Real intimacy doesn't always come from even exchanges, but from emotional transparency, especially when it's hardest to ask for and give in reciprocation.
At their core, both dismissiveness and scorekeeping aren't just poor communication habits, they're emotional coping mechanisms. One shields against vulnerability while the other pleads for recognition. But both speak to the same underlying truth: a deep need to be seen, heard and emotionally held.
Healing disconnection begins when we stop asking, 'Who's right?' and start asking, 'Where does it hurt?' Because disconnection isn't the end of love. It's a call to listen differently. It reminds us to move beyond roles and routines, and speak to each other from the tender, human places of our fears, our longings and our desire to feel safe in each other's presence.
If you've ever felt emotionally alone in the presence of your partner, know that you're not imagining it, and you're definitely not alone. Take the science-backed Loneliness In Intimate Relationships Scale to learn how it may be impacting you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
36 minutes ago
- Medscape
Fast Five Quiz: Drowning
Drowning is a significant cause of mortality. In the United States, it is the leading cause of death among children aged 1-4 years. Even when not fatal, drowning can result in permanent and severe disability due to prolonged hypoxia. Globally, drowning deaths decreased by 38% between 2000 and 2024. However, in the United States, the drowning mortality rate increased from 2019 to 2022. On average, 11 drowning deaths per day occur in the United States. Do you know the latest facts surrounding drowning? Check your knowledge with this brief quiz. There are major racial/ethnic disparities in drowning deaths and swimming ability in the United States. Although Alaska Native/non-Hispanic American Indian peoples and Black people have the highest drowning rates, the lowest rate of swimming lessons is among Hispanic adults, at only 28.1%. Comparatively, 36.9% of Black adults and 51.8% of White adults have taken swimming lessons. The overall rate of swimming lessons among all US adults is 45.3%. Learn more about drowning epidemiology. A global review on drowning prevention among children and young people found several effective strategies. In addition to placing barriers around bodies of water, the review also found wearing personal flotation devices and removing or covering water hazards to be effective in drowning prevention. Use of solar pool covers was deemed a harmful strategy because unsupervised children have become trapped under these covers and drowned. There have also been cases of drowning deaths among infants placed in baby bath seats in bathtubs. Community-based water safety awareness campaigns were rated as "promising" in the review. Although several campaigns have resulted in increased rates of personal flotation device ownership, the results vary according to the nature of the campaign and its audience. Some campaigns were noted to lack a statistically significant positive impact. Learn more about patient education on drowning. A retrospective cohort study of 406 pediatric drowning patients found that the absence of prehospital cardiac arrest, along with transfer to a high-volume hospital and indoor drowning location, were factors significantly associated with a good clinical outcome. In the study, only one patient died among the 218 patients without prehospital cardiac arrest. However, only five patients had good outcomes among the 188 patients with prehospital cardiac arrest. Patient sex, age, and prehospital time since drowning event were not significantly associated with clinical outcome. Learn more about drowning prognosis. According to American Heart Association/American Academy of Pediatrics guidelines, in-water rescue breathing should be provided to drowning victims by trained rescuers if safe. Guidelines from the Wilderness Medical Society concur. It is not necessary to wait until the patient is on dry land or in a vessel before commencing rescue breathing. Resuscitation of drowning patients should not focus on chest compressions alone. Ventilation and airway management are crucial because cardiac arrest often follows severe hypoxemia in drowning cases. Although it is prudent for water recreation areas to provide automatic external defibrillators, most drowning victims who enter cardiac arrest do not present with defibrillation-responsive rhythms. The Heimlich maneuver is not recommended in drowning because efforts to expel water from the lungs delays resuscitation and might increase the risk for vomiting and aspiration. Learn more about prehospital care in drowning. The Wilderness Medical Society does not recommend empirical antibiotics in the initial management of drowning patients. Although pneumonia might result from aspirated water, the causative microorganisms are often atypical and unresponsive to empirical antibiotic therapies. Additionally, inflammatory pneumonitis resulting from water aspiration and the stress of the drowning event may be mistaken for symptoms of infectious pneumonia. Ideally, before antibiotic administration, pneumonia should be confirmed by urinary antigen testing, sputum cultures, and/or blood cultures. Learn more about the disposition of drowning victims.
Yahoo
36 minutes ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
CBS News
36 minutes ago
- CBS News
Pennsylvania family who stayed at Ronald McDonald house shares their continued message of hope
Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope "Sarah's Painting" was created in a hospital bed by a 9-year-old going through chemotherapy. Michael Pulaski said his daughter, Sarah, loved to paint. "Which was kind of news to us, and she was actually pretty good!" Michael Pulaski said with a chuckle and smile. "It meant something to her, so it meant something to us." Now this picture is taking on a bigger meaning. "Sarah's Painting" CBS News Philadelphia. "It's been, for years, my method of communicating with the world," Sarah's brother, Ryan Pulaski, said. The 22-year-old college student is in the process of making an album. His first single was released Friday, on what would be Sarah's 25th birthday. "In Sarah's Painting, I see visions of life it should be," he sings in the song called "Sarah's Painting." It's inspired by the colorful brush strokes frozen in time. "I feel exceptionally called to create art, and it is only because I had, I have this wonderful sister who was an artist herself, that I was able to find my own voice," Ryan Pulaski said. Pulaski family. In 2010, CBS News Philadelphia caught Sarah's infectious smile on camera while walking the halls of the Children's Hospital of Philadelphia. She talked with us about a Ronald McDonald house family room for the telethon. "When we first met you, it was actually a stressful but promising time, because Sarah was in her first portions of treatment, and she was doing well," Michael Pulaski said. The pre-teen from Richboro went into remission, but later relapsed. At 11 years old, she died after a brave, long battle with leukemia. "This is my absolute favorite picture of the two of them together," Michael Pulaski said, pointing at a photo of Ryan and Sarah. Pulaski family. It's an unbreakable sibling bond — shining through photos, "Sarah's Painting," and now Ryan's song. "She'd probably tell me, I still can't sing," Ryan Pulaski said with a laugh. He continued, "But I think she would love it and be supportive all the same." As for the sibling's dad, "There aren't words, and I'm just proud." The Pulaski family said this story — it's one full of hope, to show others, a picture is worth a thousand words, a thousand memories and a love that lasts a thousand lifetimes. "I think if my 22-year-old son, who's had a probably a more difficult journey than I have, can find hope and joy, then I think the rest of us can too," Michael Pulaski said.
